J Am Pharm Assoc (2003). 2020 Jul-Aug;60(4):e70-e78. doi: 10.1016/j.japh.2020.02.017. Epub 2020 Mar 27.
This study aimed to determine the impact of an adherence intervention program on medication adherence rates and performance on the Centers for Medicare and Medicaid Services star ratings measures.
The study was conducted in a large community pharmacy chain comprising more than 2200 pharmacies and 7000 pharmacists across 36 states.
Pharmacists conducted adherence interventions with patients with a proportion of days covered (PDC) of less than 80% for hypertension, cholesterol, and diabetes star ratings medications.
A longitudinal, pharmacist-led adherence intervention program with automated follow-up interventions was implemented between June 2017 and December 2017.
The percentage of patients with a PDC of greater than or equal to 80% and performance on CMS star ratings measures were evaluated for Medicare Part D Prescription Drug Plan (PDP) and Medicare Advantage Prescription Drug (MAPD) Plan populations in 2017 compared with that of 2015 and 2016. Patient-level PDC change, pharmacist intervention completion, and pharmacist recommendation of additional pharmacy services were also measured.
A total of 241,261 interventions were generated in the electronic dispensing systems. Pharmacists enrolled 60,232 patients and completed 75.4% of follow-up interventions, with an average of 1.3 follow-ups per patient. For the Medicare PDP population, improvement in the percentage of adherent patients ranged from 1.1% to 1.2% and 0.9% to 1.8% for 2015-2016 and 2016-2017, respectively, whereas improvement ranged from 2.1% to 2.5% and 2.0% to 3.0% for 2015-2016 and 2016-2017, respectively, for the MAPD Plan population. In 2016 and 2017, performance on cholesterol and diabetes measures achieved the 4-star cut point, and the hypertension measure achieved the 5-star cut point.
This study demonstrated the successful implementation and pharmacist participation in an adherence intervention program in a large community pharmacy chain. Compared with the previous year, medication adherence improved for patients attributed to hypertension, cholesterol, and diabetes measures, and performance on CMS star rating measures was maintained, despite an increase in cut points.
本研究旨在确定依从性干预方案对药物依从率和医疗保险和医疗补助服务星级评定措施表现的影响。
该研究在一家大型社区连锁药店进行,该连锁店在 36 个州拥有 2200 多家药店和 7000 名药剂师。
药剂师对高血压、胆固醇和糖尿病星级评定药物的覆盖率(PDC)低于 80%的患者进行依从性干预。
2017 年 6 月至 12 月期间实施了一项纵向、由药剂师主导的依从性干预计划,并伴有自动化的后续干预措施。
与 2015 年和 2016 年相比,评估 2017 年医疗保险处方药计划(PDP)和医疗保险优势处方药(MAPD)计划人群中 PDC 大于或等于 80%的患者比例和 CMS 星级评定措施的表现。还测量了患者水平的 PDC 变化、药剂师干预完成情况以及药剂师推荐额外的药房服务。
电子配药系统共生成 241261 次干预。药剂师招募了 60232 名患者,并完成了 75.4%的随访干预,平均每位患者有 1.3 次随访。对于医疗保险 PDP 人群,2015-2016 年和 2016-2017 年,依从性患者的百分比分别提高了 1.1%至 1.2%和 0.9%至 1.8%,而 MAPD 计划人群则分别提高了 2.1%至 2.5%和 2.0%至 3.0%。2016 年和 2017 年,胆固醇和糖尿病措施的表现达到了 4 星级标准,高血压措施达到了 5 星级标准。
本研究表明,在大型社区连锁药店成功实施并参与了一项依从性干预计划。与前一年相比,归因于高血压、胆固醇和糖尿病措施的患者药物依从性有所提高,尽管星级评定措施的评分标准有所提高,但医疗保险和医疗补助服务星级评定措施的表现得以维持。